A short film about three spinal cord injury patients who share their stories of tragedy, hope and recovery following stem cell treatments for spinal cord injury at the Stem Cell Institute in Panama City, Panama. See them demonstrate their improvements by lifting themselves up, standing and even walking after stem cell therapy.
The dual effect of MSCs on tumour growth and tumour angiogenesis
Michelle Kéramidas, Florence de Fraipont, Anastassia Karageorgis, Anaïck Moisan, Virginie Persoons, Marie-Jeanne Richard, Jean-Luc Coll and Claire Rome
Abstract (provisional)
Introduction
Understanding the multiple biological functions played by human mesenchymal stem cells (hMSCs) as well as their development as therapeutics in regenerative medicine or in cancer treatment are major fields of research. Indeed, it has been established that hMSCs play a central role in the pathogenesis and progression of tumours, but their impact on tumour growth remains controversial.
Our results suggest that hMSCs injection decreased solid tumour growth in mice and modified tumour vasculature, which confirms hMSCs could be interesting to use for the treatment of pre-established tumours.
Methods
In this study, we investigated the influence of hMSCs on the growth of pre-established tumours. We engrafted nude mice with luciferase-positive mouse adenocarcinoma cells (TSA-Luc+) to obtain subcutaneous or lung tumours. When tumour presence was confirmed by non-invasive bioluminescence imaging, hMSCs were injected into the periphery of the SC tumours or delivered by systemic intravenous injection in mice bearing either SC tumours or lung metastasis.
Results
Regardless of the tumour model and mode of hMSC injection, hMSC administration was always associated with decreased tumour growth due to an inhibition of tumour cell proliferation, likely resulting from deep modifications of the tumour angiogenesis. Indeed, we established that although hMSCs can induce the formation of new blood vessels in a non-tumoural cellulose sponge model in mice, they do not modify the overall amount of haemoglobin delivered into the SC tumours or lung metastasis. We observed that these tumour vessels were reduced in number but were longer.
Conclusions
Our results suggest that hMSCs injection decreased solid tumour growth in mice and modified tumour vasculature, which confirms hMSCs could be interesting to use for the treatment of pre-established tumours.
Original Link: http://stemcellres.com/content/4/2/41/abstract
MS Radio – Stem cells can change our lives
On Tuesday, February 19th, 2013
at 5pm EST
Stem Cells Change Lives
Click here to Listen Online
or Call (347) 327-9317
Toll Free (877) 497-9936
Join us on Multiple Sclerosis Radio as the Director of MSstation™ Radio Judi Lecoq and her panel of nine individuals candidly share their testimonies of living with Multiple Sclerosis and their experiences after undergoing Stem Cell Treatment.
Judi Lecoq
I was diagnosed with Secondary Progressive Multiple Sclerosis in 1997, and began the Stem Cell Journey, with Fundraising January 2010.
SammyJo Wilkinson
Diagnosed ’95 relapsing remitting MS, secondary progressed by 2002. May 2012 I had adult stem cells in Houston, TX
Jennifer Ziegler
I was diagnosed with MS in 2004. I started thinking about Adult Stem Cell Therapy around 6 yrs. ago.
Holly Huber
Diagnosed with Multiple Sclerosis in 2004. Within months of my official diagnosis, I couldn’t walk. I was quickly facing having to live the rest of my life in a wheelchair and needing to depend on someone else 24/7 for survival. After 9 months of clinical research, in 2008 I had my first stem cell treatment.
Fiona Sparrow
Diagnosed 2005 with RRMS in 2009. Then I was told I had Malignant MS an extremely aggressive form. Only 3-5% of patients have this form. In December 29/2011 I underwent a full bone marrow transplant/stem cell transplant!
Annette Williams
Diagnosed with Relapsing Remitting MS in 2008. In 2010 it progressed to secondary progressive. I heard about stem cell therapy and begin researching about it. Following a fund raiser I went and had adult stem cells.
Carla Hickman
Diagnosed in May of 2003 with Relapsing Remitting Multiple Sclerosis. I began looking into stem cells in 2009 and went to Costa Rica in 2010.
Kane Roper
Diagnosed with Multiple Sclerosis for roughly 7 – 8 years, before receiving stem cell treatment last Christmas.
Richard Humphries
In October of 2005 after several hundred tonic seizures, I was diagnosed with Relapsing Remitting Multiple Sclerosis. By March 2007, it transition to Secondary Progressive MS. My wife and I were looking at a wheelchair. By the time I chose to have his first Stem Cell Treatments in 2008, I was completely bedridden. My Stem Cell Journey is long and varied.
Preston Walker
Diagnosed on Dec. 2001 with RRMS. I went down for ASC treatment on May 2008, June of 2009 and July of 2010.
Mesenchymal Stem Cells in Regenerative Medicine:Mechanisms of action, sources, and delivery options
Neil Riordan, PhD, Founder of the Stem Cell Institute in Panama City, Panama will be speaking today, Wednesday, Feb 6 at the STEMSO International Stem Cell Society 2013 Conference in Fort Lauderdale, FL.
The topic of Dr. Riordan’s discussion will be “Mesenchymal Stem Cells in Regenerative Medicine:Mechanisms of action, sources, and delivery options”
The theme for this year’s event is “Autologous Stem Cells: Who gets to decide…”
Multiple Sclerosis Radio – “Stem cells are your body’s natural healing mechanism” – Neil Riordan PhD
For anyone who missed Dr. Riordan’s talk on MS Radio yesterday, below is a link to the replay. Did you know that by age 30, 96% of the mesenchymal stem cells are gone from a person’s bone marrow? Why is MS a disease of the immune system? How can an automated machine analyze a sample of lecithin and buffer that contains no cells and show that it contains 10 million cells per ml? Tune in for these and more.
REPLAY: “Stem cells are your body’s natural healing mechanism” – Neil Riordan PhD
TODAY ON MULTIPLE SCLEROSIS RADIO!
Dr. Neil Riordan, Founder of Stem Cell Institute
Tuesday Feb 5, 2013 at 2 pm EST.
LISTEN ONLINE: Multiple Sclerosis Radio
or call in Join Us LIVE On Air
(347) 327-9317
or Toll-Free
(877) 497-9936
http://www.blogtalkradio.com/msradio/2013/02/05/stem-cells-your-bodys-natural-healing-mechanism-stem-kine-1
Liposuction method can adversely affect adipose tissue-derived stem cell yield and growth
Adipose tissue-derived mesenchymal stem cell yield and growth characteristics are affected by the tissue-harvesting procedure which was published in Cytotherapy (vol. 8 issue 2, 2006, pages 166-177)states that:
“Ultrasound-assisted liposuction resulted in a lower frequency of proliferating adult stem cells, as well as a longer population doubling time of adult stem cells, compared with resection…”
Those seeking adipose stem cell therapy should ask their doctor if he or she is using ultrasound assisted liposuction to collect the fat sample.
*Stem Cell Institute does not use ultrasound assisted liposuction.
Adipose tissue-derived mesenchymal stem cell yield and growth characteristics are affected by the tissue-harvesting procedure
M.J. Oedayrajsingh-Varma1, S.M. van Ham2, M. Knippenberg3, M.N. Helder4, J. Klein-Nulend3, T.E. Schouten5, M.J.P.F. Ritt1, F.J. van Milligen, PhD5,
1 Department of Plastic Reconstructive and Hand Surgery, VU University Medical Center, Amsterdam, the Netherlands
2 Department of Immunopathology, Sanquin Research at CLB, Amsterdam, the Netherlands
3 Department of Oral Cell Biology, ACTA-Vrije Universiteit, Amsterdam, the Netherlands
4 Department of Orthopaedic Surgery, VU University Medical Center, Amsterdam, the Netherlands
5 Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands
http://dx.doi.org/10.1080/14653240600621125, How to Cite or Link Using DOI
Permissions & Reprints
Patients beware: “Point of care” fat stem cell separation and counting kits inaccurate and not US FDA approved for humans.
An informative paper by Mary Pat Moyer, PhD detailing why “same-day” fat stem cell kits that are becoming more common in doctors’ offices across the US can miscount “stem cells” by large factors leading to over estimation of stem cell counts by as much as 20 times or more.
It also states, “no complete harvest and cell isolation systems have been approved by the FDA for autologous SVF harvest for immediate use [in humans].” These are just a couple of the arguments presented that demonstrate why it’s important to process adipose tissue properly in a professional lab setting.
Morrison DG, Hunt DA, Garza I, Johnson RA, Moyer MP*. Counting and Processing Methods Impact Accuracy of Adipose Stem Cell Doses. BioProcess J, 2012; 11(4): 4-17.